0001839882-23-013974.txt : 20230530
0001839882-23-013974.hdr.sgml : 20230530
20230530181444
ACCESSION NUMBER: 0001839882-23-013974
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230525
FILED AS OF DATE: 20230530
DATE AS OF CHANGE: 20230530
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Versi Jannine
CENTRAL INDEX KEY: 0001977745
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36242
FILM NUMBER: 23978247
MAIL ADDRESS:
STREET 1: 11682 EL CAMINO REAL
STREET 2: STE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp
CENTRAL INDEX KEY: 0000887247
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 820429727
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11682 EL CAMINO REAL
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 997-2400
MAIL ADDRESS:
STREET 1: 11682 EL CAMINO REAL
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19950615
4
1
jversi-form4_052523.xml
OWNERSHIP DOCUMENT
X0407
4
2023-05-25
0
0000887247
Adamis Pharmaceuticals Corp
ADMP
0001977745
Versi Jannine
C/O ADAMIS PHARMACEUTICALS CORPORATION
11682 EL CAMINO REAL, SUITE 300
SAN DIEGO
CA
92130
1
0
0
0
0
Common Stock
2023-05-25
4
A
0
177194
A
177194
I
By Versi Group, LLC
Employee Stock Option (Right to Buy)
2.90
2023-05-25
4
A
0
5144
A
2023-05-25
2028-02-19
Common Stock
5144
5144
D
Employee Stock Option (Right to Buy)
2.90
2023-05-25
4
A
0
5144
A
2023-05-25
2029-02-19
Common Stock
5144
5144
D
Employee Stock Option (Right to Buy)
2.90
2023-05-25
4
A
0
5144
A
2023-05-25
2030-02-19
Common Stock
5144
5144
D
Employee Stock Option (Right to Buy)
2.90
2023-05-25
4
A
0
5144
A
2023-05-25
2031-02-19
Common Stock
5144
5144
D
Employee Stock Option (Right to Buy)
2.90
2023-05-25
4
A
0
5144
A
2023-05-25
2032-02-19
Common Stock
5144
5144
D
Series E Convertible Preferred Stock
2023-05-25
4
A
0
1941.2
A
2023-05-25
Common Stock
1941200
1941.2
I
By Versi Group, LLC
On May 22, 2023, Adamis Pharmaceuticals Corporation ("Adamis") effected a 1 for 70 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
The reported shares are owned directly by Versi Group, LLC, of which the reporting person is the trustee of. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interests therein.
Received in exchange for shares of common stock of DMK Pharmaceuticals Corporation, a privately held corporation ("DMK"), in connection with the merger of DMK into a subsidiary of Adamis (the "Merger"). On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share.
Received in the Merger by virtue of the assumption of a stock option to acquire shares of DMK common stock in connection with the Merger, with proportionate adjustments to the number of shares subject to the option and the per share exercise price.
Received in the Merger in exchange for shares of common stock of DMK. Each whole share of Series E Preferred Convertible Stock is convertible into 1,000 shares of Adamis common stock at the election of the Reporting Person provided that no portion of the Series E Convertible Preferred Stock may be converted if the Reporting Person or her affiliates own in excess of 9.99% of the number of shares of Adamis common stock outstanding immediately after giving effect of such conversion. On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share.
/s/ David C. Benedicto, as Attorney-in-Fact
2023-05-30